Chargement en cours...
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
Heart failure is frequently associated with diabetes, and therapies which reduce mortality in people with heart failure and reduced ejection fraction (HFrEF) are often limited to drugs which modulate the renin–angiotensin–aldosterone system or heart rate control and occasionally to device therapy. T...
Enregistré dans:
| Publié dans: | Diabetes Ther |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Healthcare
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7434820/ https://ncbi.nlm.nih.gov/pubmed/32710261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00889-9 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|